PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study to Learn if Study Medicines Called Cyclosporine and Clarithromycin Affect How the Body Processes the Other Study Medicine Called PF-07328948 in Healthy Adults
Phase 1
Active, not recruiting
- Conditions
- Healthy Adults
- Interventions
- First Posted Date
- 2025-02-20
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 26
- Registration Number
- NCT06837259
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
A Study to Learn How Different Amounts of the Study Medicine Called PF-07314470 Are Tolerated and Act in the Body in Healthy Adults
Phase 1
Recruiting
- Conditions
- Healthy
- Interventions
- Biological: Placebo for PF-07314470
- First Posted Date
- 2025-02-12
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 103
- Registration Number
- NCT06821750
- Locations
- 🇺🇸
Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut, United States
Effectiveness of ABRYSVO® Maternal Respiratory Syncytial Virus (RSV) Vaccine Against RSV in Infants in Western Pennsylvania
Active, not recruiting
- Conditions
- Respiratory Syncytial Viruses
- Interventions
- Biological: ABRYSVO Vaccination
- First Posted Date
- 2025-02-07
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT06813872
- Locations
- 🇺🇸
Pfizer, New York, New York, United States
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
- First Posted Date
- 2025-02-04
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 150
- Registration Number
- NCT06807268
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
- First Posted Date
- 2025-02-04
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 500
- Registration Number
- NCT06807281
A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Malignant MelanomaMelanomaMetastatic MelanomaSolid Tumors
- Interventions
- First Posted Date
- 2025-01-29
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 185
- Registration Number
- NCT06799533
RITUXIMAB BS Intravenous Infusion 100mg・500mg [Pfizer] Post-marketing Database Study
- First Posted Date
- 2025-01-24
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT06790420
- Locations
- 🇯🇵
Pfizer, Tokyo, Japan
A Study to Learn About How Well the Prevnar 20 Vaccine Works for Pneumonia in People Who Are 65 Years and Older
Active, not recruiting
- Conditions
- Community-Acquired Pneumonia (CAP)
- First Posted Date
- 2025-01-17
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 22234435
- Registration Number
- NCT06782282
- Locations
- 🇺🇸
Pfizer United States, New York, New York, United States
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Phase 3
Recruiting
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2025-01-07
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1020
- Registration Number
- NCT06760637
- Locations
- 🇧🇬
Complex Oncology Center - Shumen, Shumen, Bulgaria
🇺🇸Ironwood Cancer & Research Centers, Scottsdale, Arizona, United States
🇺🇸Highlands Oncology, Rogers, Arkansas, United States
A Study to Learn More About Prevenar 20 Once it is Out in the Korean Market
Not yet recruiting
- Conditions
- Pneumococcal ImmunizationSafety
- Interventions
- First Posted Date
- 2025-01-06
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 660
- Registration Number
- NCT06760208
- Locations
- 🇰🇷
Pfizer Korea, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath